Borealis Ventures

Borealis Ventures is a venture capital firm founded in 2002 and based in Hanover, New Hampshire, with an additional office in Portsmouth. The firm specializes in seed and early to mid-stage investments, focusing on emerging companies primarily in the life sciences, healthcare, digital health, information technology, and design and engineering software sectors. Borealis Ventures aims to partner with exceptional entrepreneurs to build market-defining companies, particularly in areas such as 3D design and construction management. The firm typically invests between $0.1 million and $2.5 million in portfolio companies that have sales values up to $10 million and enterprise values up to $20 million. Borealis Ventures prefers to lead investments but is also open to co-investing with other firms or entrepreneurs. The firm is committed to taking board seats in its portfolio companies and has a specific focus on the North Boston and Northern New England regions.

Charlie Carey

Principal

Phil Ferneau

Co-Founder and Managing Director

Ben Shaw

Partner

Past deals in New Hampshire

Avitide

Series E in 2017
Avitide, Inc. specializes in the discovery, manufacturing, and supply of molecule-specific affinity purification solutions tailored for the biopharmaceutical industry. The company focuses on developing customized affinity separation technology that streamlines bioprocess development, minimizes program risks, enhances predictability in commercial scalability, and lowers manufacturing costs. Its innovative affinity purification solutions cater to the production of various life-saving therapeutics, including enzymes, novel scaffolds, multi-specific antibodies, gene therapies, and vaccines. Incorporated in 2012 and based in Lebanon, New Hampshire, Avitide is recognized for its rapid development service timeline, positioning itself as a key player in the biopharmaceutical sector.

Avitide

Series C in 2015
Avitide, Inc. specializes in the discovery, manufacturing, and supply of molecule-specific affinity purification solutions tailored for the biopharmaceutical industry. The company focuses on developing customized affinity separation technology that streamlines bioprocess development, minimizes program risks, enhances predictability in commercial scalability, and lowers manufacturing costs. Its innovative affinity purification solutions cater to the production of various life-saving therapeutics, including enzymes, novel scaffolds, multi-specific antibodies, gene therapies, and vaccines. Incorporated in 2012 and based in Lebanon, New Hampshire, Avitide is recognized for its rapid development service timeline, positioning itself as a key player in the biopharmaceutical sector.

Adored

Seed Round in 2015
Adored, Inc. is a loyalty experience platform that offers a mobile application designed for restaurants, bars, coffee shops, ski resorts, and various attractions. The app utilizes iBeacon indoor location technology to automatically reward customers, enhancing their experiences and encouraging repeat visits. By fostering relationships between businesses and their loyal customers, Adored aims to influence casual visitors and attract new clientele. The application, available on both Apple iOS and Android devices, has been downloaded over 10,000 times and is active in numerous locations. Founded in 2014 and based in Manchester, New Hampshire, Adored focuses on building brand loyalty and increasing the lifetime value of customers through innovative rewards and engaging experiences.

Newforma

Series D in 2013
Newforma develops and supports project information management (PIM) software tailored for the architecture, engineering, and construction (AEC) sectors. Founded in 2003 and headquartered in Manchester, New Hampshire, the company's mission is to enhance collaboration among firms, streamline project information, and integrate processes for improved project delivery. Newforma's solutions facilitate collaboration among owners, designers, builders, and extended construction teams through mobile, cloud, and desktop applications. The software is utilized to manage information on over 1.4 million projects globally, which helps clients increase productivity, reduce risk exposure, and focus on their core activities, including design and client service.

Avitide

Series A in 2013
Avitide, Inc. specializes in the discovery, manufacturing, and supply of molecule-specific affinity purification solutions tailored for the biopharmaceutical industry. The company focuses on developing customized affinity separation technology that streamlines bioprocess development, minimizes program risks, enhances predictability in commercial scalability, and lowers manufacturing costs. Its innovative affinity purification solutions cater to the production of various life-saving therapeutics, including enzymes, novel scaffolds, multi-specific antibodies, gene therapies, and vaccines. Incorporated in 2012 and based in Lebanon, New Hampshire, Avitide is recognized for its rapid development service timeline, positioning itself as a key player in the biopharmaceutical sector.

Mosaic Storage Systems

Series A in 2013
Mosaic Storage Systems is a company that specializes in digital asset storage services, primarily catering to professional photographers. Founded in 2011 and located in Nashua, New Hampshire, the company offers automated online photo backup solutions, particularly for users of Adobe Lightroom. Its services allow photographers to store digital copies of their images on secure servers, enabling easy access and sharing via the internet. This focus on secure and efficient storage meets the growing demand for reliable photograph management in the digital age.

PCD Partners

Venture Round in 2011
PCD Partners, Inc. specializes in developing and delivering web-based platforms tailored for healthcare organizations, including physician groups, hospitals, and accountable care organizations in the United States. The company focuses on fostering collaboration between hospitals and physicians to enhance clinical outcomes and financial performance. PCD Partners offers a co-management solution that facilitates the integration of healthcare systems and improves overall performance. Additionally, it provides a cloud-based platform that supports healthcare alignment structures and quality improvement initiatives. The company also offers training programs in Lean Six Sigma methodologies, along with project management software designed specifically for healthcare delivery. Based in Lebanon, New Hampshire, PCD Partners comprises a team of experienced physicians, academics, and entrepreneurs dedicated to advancing medical quality and practice improvement.

Adimab

Series D in 2010
Adimab LLC is engaged in the discovery, development, and optimization of human monoclonal and bispecific antibodies, primarily targeting the pharmaceutical biotechnology sector. Founded in 2007 and based in Lebanon, New Hampshire, Adimab utilizes an integrated antibody discovery platform that allows for rapid development of full-length human immunoglobulins, including IgG and bispecific antibodies. The company focuses on delivering diverse panels of therapeutically relevant antibodies that meet high standards for affinity, epitope coverage, species cross-reactivity, and expressibility. By leveraging its yeast-based technology, Adimab enhances the quality of therapeutic leads, enabling the treatment of various conditions, including cancer, autoimmune disorders, and infectious diseases. The company's innovative approach facilitates its partners in expanding their biologics pipelines through a range of technology access arrangements.

Adimab

Series C in 2008
Adimab LLC is engaged in the discovery, development, and optimization of human monoclonal and bispecific antibodies, primarily targeting the pharmaceutical biotechnology sector. Founded in 2007 and based in Lebanon, New Hampshire, Adimab utilizes an integrated antibody discovery platform that allows for rapid development of full-length human immunoglobulins, including IgG and bispecific antibodies. The company focuses on delivering diverse panels of therapeutically relevant antibodies that meet high standards for affinity, epitope coverage, species cross-reactivity, and expressibility. By leveraging its yeast-based technology, Adimab enhances the quality of therapeutic leads, enabling the treatment of various conditions, including cancer, autoimmune disorders, and infectious diseases. The company's innovative approach facilitates its partners in expanding their biologics pipelines through a range of technology access arrangements.

Newforma

Series C in 2008
Newforma develops and supports project information management (PIM) software tailored for the architecture, engineering, and construction (AEC) sectors. Founded in 2003 and headquartered in Manchester, New Hampshire, the company's mission is to enhance collaboration among firms, streamline project information, and integrate processes for improved project delivery. Newforma's solutions facilitate collaboration among owners, designers, builders, and extended construction teams through mobile, cloud, and desktop applications. The software is utilized to manage information on over 1.4 million projects globally, which helps clients increase productivity, reduce risk exposure, and focus on their core activities, including design and client service.

Newforma

Series C in 2007
Newforma develops and supports project information management (PIM) software tailored for the architecture, engineering, and construction (AEC) sectors. Founded in 2003 and headquartered in Manchester, New Hampshire, the company's mission is to enhance collaboration among firms, streamline project information, and integrate processes for improved project delivery. Newforma's solutions facilitate collaboration among owners, designers, builders, and extended construction teams through mobile, cloud, and desktop applications. The software is utilized to manage information on over 1.4 million projects globally, which helps clients increase productivity, reduce risk exposure, and focus on their core activities, including design and client service.

GlycoFi Inc.

Series C in 2005
GlycoFi is a biotech firm that develops biotherapeutics based on the glycan optimization technology. The firm aims to develop its own pipeline of therapeutic proteins and team with other drug-makers to develop products. GlycoFi has developed a protein manufacturing process using yeast-based glycolysation where the resulting proteins can be used in drug development. GlycoFi was incorporated in 2000 and is based in Lebanon, New Hampshire. As of June 6, 2006, GlycoFi, Inc. operates as a subsidiary of Merck & Co. Inc.

Newforma

Series B in 2005
Newforma develops and supports project information management (PIM) software tailored for the architecture, engineering, and construction (AEC) sectors. Founded in 2003 and headquartered in Manchester, New Hampshire, the company's mission is to enhance collaboration among firms, streamline project information, and integrate processes for improved project delivery. Newforma's solutions facilitate collaboration among owners, designers, builders, and extended construction teams through mobile, cloud, and desktop applications. The software is utilized to manage information on over 1.4 million projects globally, which helps clients increase productivity, reduce risk exposure, and focus on their core activities, including design and client service.

Medical Metrx Solutions

Series B in 2003
Medical Metrx Solutions, Inc. (formerly Medical Media Systems) is a medical technology and services company providing diagnostic quality 3-D virtual models of patient anatomy built from CT and MR scan data using the company’s proprietary modeling software. The company’s models — which contain more precise quantitative measurement information than competitors’ offerings — are provided to interventional radiologists and vascular surgeons who use them for pre-operative planning and post-operative surveillance of their patients’ conditions. The company was acquired by AIG Altaris Health Partners in 2005.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.